Figure 3
Increased pulmonary expression of Lipocalin-2 in RAS. Immunohistochemistry: Pulmonary Lipocalin-2 expression in bronchial walls of a RAS patient. [(A) scale bar: 400 µm]; in contrast, absent expression of Lipocalin-2 in bronchial walls of a healthy control lung [(B) scale bar: 400 µm]. Lipocalin-2 expression in alveolar pneumocytes of a RAS patient [(C) scale bar: 80 µm]. No Lipocalin-2 expression in alveolar pneumocytes of a BO patient [(D) scale bar: 80 µm]. Elastica-van-Gieson staining detecting BO lesions [(E) scale bar: 400 µm]. Adjacent slide to (E) showing no increased expression of Lipocalin-2 within a BO lesion [(F) scale bar: 400 µm]. Discrete Lipocalin-2 expression in bronchial walls of an IPF patient [(G) scale bar: 160 µm] and a CF patient [(H) scale bar: 400 µm]. RAS Restrictive allograft syndrome, BO bronchiolitis obliterans, CF cystic fibrosis, IPF idiopathic pulmonary fibrosis.
